Tfaily Mohamad Ali, Tamim Hani, El Hajj Albert, Mukherji Deborah
Department of Internal Medicine, Emory University, Atlanta, GA 30322, USA.
Department of Internal Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon.
Ecancermedicalscience. 2022 Oct 18;16:1456. doi: 10.3332/ecancer.2022.1456. eCollection 2022.
Radical cystectomy (RC) for muscle invasive bladder cancer (MIBC) remains the historical gold standard for treatment despite significant perioperative morbidity and subsequent quality of life concerns. Trimodal therapy (TMT) is gaining acceptance as an alternative bladder preserving approach. We aim to identify patients for whom TMT may be the optimal approach by constructing risk calculators of morbidity and mortality associated with RC.
Using the American College of Surgeons National Surgical Quality Improvement Program database, we selected patients diagnosed with MIBC undergoing RC, with a total of 10,642 patients identified. The primary outcome was mortality and secondary outcome was morbidity within 30 days of the procedure. We conducted multivariate logistic regression to obtain the best fit model for each outcome on 70% of the sample. Validation of the models was then performed on the remaining 30% of the sample. Model performance was assessed using discrimination and calibration abilities and a risk calculator was constructed for pre-operative counselling.
Of the full cohort, 199 patients (1.9%) died and 2,328 patients (21.9%) experienced morbidity. Variables selected for the model predicting mortality included age, frailty, the American Society of Anesthesiologists status and preoperative creatinine. For the mortality model, the area under the curve was 72% with a Hosmer-Lemeshow statistic of 0.722. For the morbidity model, the area under the curve was 60% with a Hosmer-Lemeshow statistic of 0.287. Variables significant in the model included continent diversion, smoking and frailty.
We have constructed statistically significant and clinically relevant models using readily available health indicators to be used in multi-disciplinary discussion to provide high-risk patients with individualised risks of morbidity and mortality from RC, allowing for counselling for alternative treatments such as TMT.
对于肌层浸润性膀胱癌(MIBC),根治性膀胱切除术(RC)仍然是传统的治疗金标准,尽管围手术期发病率较高且会影响后续生活质量。三联疗法(TMT)作为一种保留膀胱的替代方法正逐渐被接受。我们旨在通过构建与RC相关的发病率和死亡率风险计算器,确定TMT可能是最佳治疗方法的患者。
利用美国外科医师学会国家外科质量改进计划数据库,我们选取了被诊断为MIBC并接受RC的患者,共识别出10642例患者。主要结局是死亡率,次要结局是术后30天内的发病率。我们进行多因素逻辑回归分析,以获得样本中70%的每个结局的最佳拟合模型。然后在其余30%的样本上对模型进行验证。使用区分能力和校准能力评估模型性能,并构建风险计算器用于术前咨询。
在整个队列中,199例患者(1.9%)死亡,2328例患者(21.9%)出现并发症。预测死亡率的模型所选变量包括年龄、虚弱程度、美国麻醉医师协会分级和术前肌酐水平。对于死亡率模型,曲线下面积为72%,Hosmer-Lemeshow统计量为0.722。对于发病率模型,曲线下面积为60%,Hosmer-Lemeshow统计量为0.287。模型中具有显著意义的变量包括可控性尿流改道、吸烟和虚弱程度。
我们利用易于获取的健康指标构建了具有统计学意义和临床相关性的模型,用于多学科讨论,为高危患者提供RC导致发病和死亡的个体化风险,以便为TMT等替代治疗提供咨询。